News

PMLive8m
Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer
Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...
Halozyme Therapeutics: The Waters Become Muddled
Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support ...